B1-Metallo-β-Lactamases: Where Do We Stand?

Area of Science:

• Microbiology
• Structural Biology
• Drug Discovery

Background:

• Metallo-β-lactamases (MBLs) are critical enzymes conferring resistance to β-lactam antibiotics.
• MBLs belong to the metallo-hydrolase superfamily, characterized by a conserved αβ/βα fold and zinc-dependent activity.
• Class B1 MBLs, including NDM-1, IMP-1, and VIM-2, are of significant clinical concern due to their broad substrate spectrum.

Purpose of the Study:

• To review the molecular epidemiology of clinically significant class B1 MBLs.
• To discuss structural studies of prominent B1 MBLs (NDM-1, IMP-1, VIM-2).
• To explore implications of structural and mechanistic diversity for the design of novel MBL inhibitors.

Main Methods:

• Literature review of molecular epidemiology data.
• Analysis of published structural studies on NDM-1, IMP-1, and VIM-2.
• Comparative analysis of active site architectures and catalytic mechanisms.

Main Results:

• Class B1 MBLs exhibit diverse active site configurations and zinc coordination, complicating inhibitor development.
• Specific examples like NDM-1, IMP-1, and VIM-2 highlight the challenges posed by these enzymes.
• Understanding these structural differences is key to designing effective inhibitors.

Conclusions:

• The structural and mechanistic heterogeneity of class B1 MBLs presents a significant hurdle for developing broad-spectrum inhibitors.
• Targeted inhibitor design strategies are needed to address the growing threat of MBL-producing bacteria.
• Further research into MBL structure-activity relationships is crucial for combating antibiotic resistance.